David G Hicks
Affiliation: Cleveland Clinic Foundation
- Assessment of the HER2 status in breast cancer by fluorescence in situ hybridization: a technical review with interpretive guidelinesDavid G Hicks
Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Hum Pathol 36:250-61. 2005..The development of automated platforms for hybridization, image analysis for signal enumeration, and experience with FISH interpretation should broaden the availability of this technology for clinical diagnostic testing...
- Loss of breast cancer metastasis suppressor 1 protein expression predicts reduced disease-free survival in subsets of breast cancer patientsDavid G Hicks
Department of Clinical and Anatomic Pathology, General Surgery Breast Center, Lerner Research Institute, The Cleveland Clinic, Cleveland, Ohio 44195, USA
Clin Cancer Res 12:6702-8. 2006....
- HER2 status in bilateral breast cancerJoseph P Crowe
Departments of General Surgery Breast Center, The Cleveland Clinic, Cleveland, Ohio 44195, USA
Int J Fertil Womens Med 51:219-23. 2006..The purpose of this study was to identify correlates of HER2 status for patients with bilateral breast cancer...
- Automation of manual components and image quantification of direct dual label fluorescence in situ hybridization (FISH) for HER2 gene amplification: A feasibility studyRaymond R Tubbs
Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, USA
Appl Immunohistochem Mol Morphol 14:436-40. 2006..Operational gains and enhanced consistency are inherent in this automated approach to HER2 clinical FISH testing...
- Fluorescence in situ hybridization (FISH) as primary methodology for the assessment of HER2 Status in adenocarcinoma of the breast: a single institution experienceRaymond R Tubbs
Anatomic and Clinical Pathology, Cleveland Clinic Foundation and the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
Diagn Mol Pathol 16:207-10. 2007..0 or more in at least 80% of tumor cells, was observed in 3% (20/742) of the cases. These data may be helpful as benchmarks for other institutions initiating primary FISH analysis for HER2 genotyping...
- The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical studySarah M Short
Department of Anatomic and Clinical Pathology L25, Cleveland, Ohio, USA
Breast J 13:130-9. 2007..Further study of a role for paxillin expression in predicting response to cytotoxic regimens or targeted treatments is warranted...
- The influence of polysomy 17 on HER2 gene and protein expression in adenocarcinoma of the breast: a fluorescent in situ hybridization, immunohistochemical, and isotopic mRNA in situ hybridization studyErinn Downs-Kelly
Department of Anatomical and Clinical Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Am J Surg Pathol 29:1221-7. 2005..These results suggest that chromosome 17 polysomy in the absence of HER2 amplification does not have a significant biologic influence on HER2 gene expression in breast carcinoma...
- An approach to the validation of novel molecular markers of breast cancer via TMA-based FISH scanningRaymond R Tubbs
Departments of Anatomical and Clinical Pathology, The Cleveland Clinic Foundation, The Lerner College of Medicine, Cleveland, OH 44195, USA
J Mol Histol 38:141-50. 2007....
- Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFRDavid G Hicks
Clinical and Anatomic Pathology, Cleveland Clinic Foundation, OH 44195, USA
Am J Surg Pathol 30:1097-104. 2006....
- Delay to formalin fixation 'cold ischemia time': effect on ERBB2 detection by in-situ hybridization and immunohistochemistryBryce P Portier
Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, OH, USA
Mod Pathol 26:1-9. 2013..On the basis of our findings, cold ischemia time up to 3 h has no deleterious effect on the detection of ERBB2 via in-situ hybridization or IHC...
- A data model to predict HER2 status in breast cancer based on the clinical and pathologic profiles of a large patient population at a single institutionJoseph P Crowe
Department of General Surgery Breast Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk A 80, Cleveland, OH 44195, USA
Breast 15:728-35. 2006..Correlates of HER2 amplification were higher Scarff-Bloom-Richardson grade, younger age at diagnosis, and a comedo ductal carcinoma in situ component...
- The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization studyDavid G Hicks
Department of Anatomic Pathology, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Hum Pathol 36:348-56. 2005..If TOP2A gene dosage can be confirmed to correlate with tumor responsiveness to anthracycline-based therapy in the clinical setting, FISH testing for TOP2A status may be warranted to aid in the selection of the most appropriate therapy...
- Analysis of gene expression in mineralized skeletal tissues by laser capture microdissection and RT-PCRYvonne Y Shao
Orthopaedic Research Center, Department of Orthopaedic Surgery, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
Lab Invest 86:1089-95. 2006....
- High-resolution immunophenotyping of subcellular compartments in tissue microarrays by enzyme metallographyRaymond Tubbs
Department of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation, OH 44195, USA
Appl Immunohistochem Mol Morphol 13:371-5. 2005..This preliminary study shows the utility of using enzyme metallography for high-resolution immunophenotyping in TMAs...
- SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubismSteven A Lietman
Department of Orthopaedic Surgery, Cleveland Clinic, Cleveland, OH 44195, USA
Clin Orthop Relat Res 459:22-7. 2007..Although many multinucleated giant cell lesions of bone share histologic features, the primary genetic defect in cherubism and these other giant cell lesions appears different...
- The expression of fascin, an actin-bundling motility protein, correlates with hormone receptor-negative breast cancer and a more aggressive clinical courseBrian J Yoder
Department of Anatomic Pathology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Clin Cancer Res 11:186-92. 2005..If so, then fascin may represent a new molecular target for therapeutic intervention in patients with ER-negative breast cancer...
- Expression and activation of peroxisome proliferator-activated receptors in growth plate chondrocytesYvonne Y Shao
Departments of Orthopaedic Surgery and Biomedical Engineering, Orthopaedic Research Center, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
J Orthop Res 23:1139-45. 2005....
- In situ hybridization in the pathology laboratory: general principles, automation, and emerging research applications for tissue-based studies of gene expressionDavid G Hicks
Departments of Anatomic and Clinical Pathology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
J Mol Histol 35:595-601. 2004..This review will focus on the emerging role of in situ hybridization within clinical and research laboratories, and will highlight a number of technical advances that have expanded the application of this technology...
- Trastuzumab as adjuvant therapy for early breast cancer: the importance of accurate human epidermal growth factor receptor 2 testingDavid G Hicks
Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, NY 14642, USA
Arch Pathol Lab Med 132:1008-15. 2008..In all 4 trials, disease-free survival and overall survival were significantly improved with adjuvant trastuzumab (36%-52% and 33%-41%, respectively), and improvements were observed in all patient subgroups...
- HER-2 testing in breast cancerRaymond R Tubbs
JAMA 292:1817-8; author reply 1818. 2004
- Candidate glioblastoma development gene identification using concordance between copy number abnormalities and gene expression level changesKen C Lo
Department of Cancer Genetics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Genes Chromosomes Cancer 46:875-94. 2007..This genome wide screen provides an efficient and comprehensive survey of genes which potentially serve as the drivers for the CNAs in GBM...
- Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancerBrian Z Ring
Applied Genomics Inc, 863 Mitten Rd 103, Burlingame, CA, USA
J Clin Oncol 24:3039-47. 2006..We have used gene expression data to guide the production of hundreds of novel antibody reagents to discover novel diagnostic tools for stratifying carcinoma patients...
- A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibilityWilliam C Powell
Ventana Medical Systems Inc, Tucson, AZ, USA
Appl Immunohistochem Mol Morphol 15:94-102. 2007..3% SI) in both cohorts. Interlaboratory reproducibility was also excellent (kappa 1.0). RMoAb 4B5 provides excellent sensitivity, specificity, and interlaboratory reproducibility for the detection of HER2 status in breast cancer...
- HER2-positive early breast cancer and trastuzumab: a surgeon's perspectiveSwati Kulkarni
Department of Surgical Oncology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
Ann Surg Oncol 15:1677-88. 2008..If trastuzumab is approved for use in neoadjuvant regimens, the need for surgeons to be well informed about the appropriate use of this particular agent will become even more important...
- HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic toolsDavid G Hicks
Department of Pathology and Laboratory Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Am J Clin Pathol 129:263-73. 2008..Rigorous quality control and standardization of the testing process, from the handling of tissue samples to interpretation and reporting of results, are essential for achieving accurate and reproducible assay results...
- The role of the indispensable surgical pathologist in treatment planning for breast cancerDavid G Hicks
Arch Pathol Lab Med 132:1226-7. 2008
- Down-regulation of WAVE3, a metastasis promoter gene, inhibits invasion and metastasis of breast cancer cellsKhalid Sossey-Alaoui
Roswell Park Cancer Institute, Department of Cancer Genetics, Elm and Carlton Streets, Buffalo, NY 14263, USA
Am J Pathol 170:2112-21. 2007..These studies provide direct evidence that the WAVE3-p38 pathway contributes to breast cancer progression and metastasis...
- The unmet clinical need for new molecular genetic markers in the prognosis and therapeutic management of breast cancerDavid G Hicks
Arch Pathol Lab Med 129:1372-4. 2005
- Prostate-derived Ets transcription factor (PDEF) downregulates survivin expression and inhibits breast cancer cell growth in vitro and xenograft tumor formation in vivoAli Ghadersohi
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA
Breast Cancer Res Treat 102:19-30. 2007..Furthermore, loss of PDEF expression in breast cancer tissues tends to be associated with unfavorable prognosis. These studies provide new information for the role of PDEF and survivin in breast cancer cell growth and tumor formation...
- Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesionsRaja R Seethala
University of Pennsylvania Medical Center, Philadelphia, PA 19104, USA
Mod Pathol 17:1491-6. 2004..These findings support the notion that giant cells in giant cell lesions are likely derived from adjacent mononuclear cells and Mitf might play a role in the multinucleation process of such cells...